Feasibility and low toxicity of early radiotherapy after highâ•'dose chemotherapy and autologous stem cell transplantation
Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy
Clinical effectiveness of seasonal influenza vaccine among adult cancer patients
The Influence of Mucositis on Oral Thermometry: When Fever May Not Reflect Infection
Staphylococcus Coagulase‐Positive Skin Inflammation Associated with Epidermal Growth Factor Receptor‐Targe
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Collaterals
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
WP2: Resilience Definition and operationalization
Prof. Salomon Stemmer – CTG-Pharma
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast can
Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
Pasireotide for malignant insulinoma
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
White Matter Changes in Patients with Breast Cancer Treated with High-Dose Chemotherapy and Autologous Bone Marrow Support
ESMO Congress 2021 Speakers Template
This gives hope': A third COVID-19 vaccine dose can boost protection for organ transplant recipients | Science | AAAS
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
Durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: Three-month follo
Why is end-of-life spending so high? Evidence from cancer patients
Cancers | Free Full-Text | Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
NBER WORKING PAPER SERIES WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS Dan Zeltzer Liran Einav Amy Finkels
